About Ottimo Pharma
Ottimo Pharma is a company based in Dover (United Kingdom) founded in 2020. Ottimo Pharma has raised $140 million across 1 funding round from investors including J P Morgan, Orbimed and Janus Henderson Investors. Ottimo Pharma offers products and services including PD1/VEGFR2 Dual Antibodies. Ottimo Pharma operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Dover, United Kingdom
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Jurisdiction Mumbai, Maharashtra, India
-
Annual Revenue
$15.56 K (USD)0as on Mar 31, 2017
-
Net Profit
$230.02 (USD)0as on Mar 31, 2017
-
EBITDA
$8.87 K (USD)0as on Mar 31, 2017
-
Total Equity Funding
$140 M (USD)
in 1 rounds
-
Latest Funding Round
$140 M (USD), Series A
Dec 19, 2024
-
Investors
J P Morgan
& 8 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Ottimo Pharma
Ottimo Pharma offers a comprehensive portfolio of products and services, including PD1/VEGFR2 Dual Antibodies.
Innovative antibodies targeting PD1 and VEGFR2 pathways for cancer treatment.
People of Ottimo Pharma
Unlock access to complete
Funding Insights of Ottimo Pharma
Ottimo Pharma has successfully raised a total of $140M through 1 strategic funding round. The most recent funding activity was a Series A round of $140 million completed in December 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Ottimo Pharma
Ottimo Pharma has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include J P Morgan, Orbimed and Janus Henderson Investors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Locked | Locked | Locked | |
|
Venture capital fund focused on biotechnology startups
|
Locked | Locked | Locked | |
|
Venture capital funding is provided by Samsara BioCapital in California.
|
Locked | Locked | Locked |
Investor details for Ottimo Pharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Ottimo Pharma
Investment portfolio details for Ottimo Pharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Ottimo Pharma
Detailed financials for Ottimo Pharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Ottimo Pharma Comparisons
Peer comparison for Ottimo Pharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Ottimo Pharma
Ottimo Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
Detailed competitors of Ottimo Pharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Ottimo Pharma
Complete news archive for Ottimo Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ottimo Pharma
Ottimo Pharma was founded in 2020 and raised its 1st funding round 4 years after it was founded.
Ottimo Pharma is headquartered in Dover, United Kingdom.
Ottimo Pharma is a funded company, having raised a total of $140M across 1 funding round to date.
Annual revenue of Ottimo Pharma is $15.56K as on Mar 31, 2017.
Ottimo Pharma was founded in 2020 and is based in Dover, United Kingdom. Focus is placed on the biotechnology sector, where bifunctional medicines for cancer treatment are developed. Antibodies targeting PD1 and VEGFR2 are combined in these drugs to address solid tumors and various other cancers. Operations center on research and drug innovation within oncology.
Ottimo Pharma's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Ottimo Pharma offers PD1/VEGFR2 Dual Antibodies.
Ottimo Pharma has 9 investors. Key investors include J P Morgan, Orbimed, Janus Henderson Investors, RTW Investments, and Avoro Capital Advisors.